A Revolution
in Cardiac Valves


  1. anticoagulation-free

  2. lasts for life

  3. silent


Novostia SA is dedicated to advancing this innovative medical device to clinical trials and regulatory approvals. 


  1. Finally, an answer to a large and growing unmet need worldwide—especially among young patients in developed and emerging economies.


  2. Preclinical evidence supporting product safety and effectiveness.


  3. Support from internationally renowned cardiac surgeons and fluid dynamics experts.





 Discover which patients may benefit from the Lapeyre-Triflo valve

I have been impressed by the Lapeyre-Triflo valve and
look forward to starting  first-in-man clinical trials.

This valve has the potential to benefit thousands of patients, especially young people.


Prof. Thierry Carrel, M.D.
University Hospital of Bern, Switzerland


Discover our key opinion leaders

 A new generation of artificial valves
combining the best of existing worlds


New high-performance biocompatible material.
A unique anatomic tri-leaflet design with a physiological operating mode.

Like native valves, the Lapeyre-Triflo valve closes early and gently during flow deceleration
and not by the reverse flow as in current mechanical heart valves—
thus not generating a haemostatic response.


Discover the Lapeyre-Triflo valve